Who are Ticagrelor maintenance dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clopidogrel, cilostazol, aspirin and/or clopidogrel, Dabigatran + clopidogrel, clopidogrel + aspirin OR prasugrel + aspirin, OAC + clopicogrel, Clopidogrel only.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-maintenance-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ticagrelor maintenance dose — Competitive Intelligence Brief

Ticagrelor maintenance dose (Ticagrelor maintenance dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 platelet receptor antagonist. Area: Cardiovascular.

marketed P2Y12 platelet receptor antagonist P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ticagrelor maintenance dose (Ticagrelor maintenance dose) — Icahn School of Medicine at Mount Sinai. Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ticagrelor maintenance dose TARGET	Ticagrelor maintenance dose	Icahn School of Medicine at Mount Sinai	marketed	P2Y12 platelet receptor antagonist	P2Y12 receptor
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
aspirin and/or clopidogrel	aspirin and/or clopidogrel	Asan Medical Center	marketed	Antiplatelet agent	COX (aspirin); P2Y12 receptor (clopidogrel)
Dabigatran + clopidogrel	Dabigatran + clopidogrel	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor
clopidogrel + aspirin OR prasugrel + aspirin	clopidogrel + aspirin OR prasugrel + aspirin	Abbott Medical Devices	marketed	Dual antiplatelet therapy (DAPT)	P2Y12 receptor (clopidogrel/prasugrel) and cyclooxygenase (aspirin)
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)
Clopidogrel only	Clopidogrel only	Seung-Jung Park	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 platelet receptor antagonist class)

Icahn School of Medicine at Mount Sinai · 2 drugs in this class
Collegium Medicum w Bydgoszczy · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticagrelor maintenance dose — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-maintenance-dose. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab